Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
Related Presenters
Medical Oncology
Physician Chief, Division of Breast Oncology, Susan F. Smith Center for Women's Cancers Associate Director, Susan F. Smith Center for Women's Cancers Senior Physician Associate Professor of Medicine, Harvard Medical School Clinical ...
Related Videos
